D&D Pharmatech Inc.

8 patents currently held · Updated Nov 14, 2026

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Ending by 2030

Nov 2027

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Mar 10, 2027
The maintenance fee for Exendin-4 analogue pegylated with polyethylene glycol or derivative thereof, preparation method thereof, and pharmaceutical composition for preventing or treating diabetes, containing same as active ingredient (US 10,406,230) comes due Mar 10, 2027. Unpaid by Sep 10, 2027, it lapses early.
1 fee due Oct 26, 2027
The maintenance fee for N-Terminal Modified Peg-Trail (US 9,321,825) comes due Oct 26, 2027. Unpaid by Apr 26, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 8 of 8

Patent	Title	Status	Expires	Confidence
US 8,420,598	Mono modified exendin with polyethylene glycol or its derivatives and uses thereof In force Term ends Nov 25, 2027 · From the USPTO record	In force	Term ends Nov 25, 2027	From the USPTO record
US 8,466,103	Exendin polypeptide linked to biotin, method for the preparation thereof and pharmaceutical composition comprising the same In force Term ends Jun 1, 2028 · From the USPTO record	In force	Term ends Jun 1, 2028	From the USPTO record
US 9,321,825	N-Terminal Modified Peg-Trail In force Term ends Jan 20, 2030 · High confidence	In force	Term ends Jan 20, 2030	High confidence
US 10,406,230	Exendin-4 analogue pegylated with polyethylene glycol or derivative thereof, preparation method thereof, and pharmaceutical composition for preventing or treating diabetes, containing same as active ingredient In force Term ends Aug 29, 2032 · From the USPTO record	In force	Term ends Aug 29, 2032	From the USPTO record
US 9,901,620	Trail receptor agonists for treatment of fibrotic disease In force Term ends Mar 11, 2035 · From the USPTO record	In force	Term ends Mar 11, 2035	From the USPTO record
US 11,299,528	Long acting TRAIL receptor agonists for treatment of autoimmune diseases In force Ends no later than Mar 11, 2035 · From the USPTO record	In force	Ends no later than Mar 11, 2035	From the USPTO record
US 10,046,059	Methods of Administering an N-Terminal Modified Peg-Trail In force Term ends Apr 25, 2036 · High confidence	In force	Term ends Apr 25, 2036	High confidence
US 12,338,270	Pharmaceutical Composition Comprising Polypeptide In force Term ends Feb 21, 2042 · High confidence	In force	Term ends Feb 21, 2042	High confidence

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

5 pending · 1 no status recorded

List them